Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 study of SPR720 for Mycobacterium avium complex pulmonary disease was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Avium Complex
• Non-tuberculosis Mycobacterium Pulmonary Disease

Drugs mentioned

• SPR720 (SPR720)

Snippet

Sponsor: Spero Therapeutics | Conditions: Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease | Phase 2 | Status: TERMINATED | Results posted: 2022-02-28